Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 After Oral Administration in Healthy Male Subjects.

Trial Profile

Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 After Oral Administration in Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2013

At a glance

  • Drugs LC 350189 (Primary) ; Febuxostat
  • Indications Gout
  • Focus Adverse reactions
  • Sponsors LG Life Sciences
  • Most Recent Events

    • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Apr 2012 Planned number of patients changed from 72 to 102 as reported by ClinicalTrials.gov.
    • 27 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top